ADVFN - Advanced Financial Network.
HOME» NASDAQ » H » HGSI Stock Price » HGSI Stock News

Human Genome Sciences Share News

 Human Genome Sciences (mm) Stock Price
HGSI Stock Price
 Human Genome Sciences (mm) Stock Chart
HGSI Stock Chart
 Human Genome Sciences (mm) Stock News
HGSI Stock News
 Human Genome Sciences (mm) Company Information
HGSI Company Information
 Human Genome Sciences (mm) Stock Trades
HGSI Stock Trades

GlaxoSmithKline Offer To Acquire HGS Represents Full, Fair Value

LONDON -(Dow Jones)- GlaxoSmithKline PLC (GSK.LN), a British pharmaceutical company, said Thursday it believes its tender offer for Human Genome Sciences(HGSI) represents full and fair value and is in the best interests of both companies' shareholders, adding that it will continue to proceed with its tender offer. MAIN FACTS: -The offer represents a premium of 81 percent to HGS's closing share price of $7.17 on April 18. -Tender offer to acquire all of Human Genome Sciences outstanding shares for $13.00 per share in cash. -The offer is not conditioned on due diligence or financing. -The tender offer will close on June 7. -GSK's offer incorporates the value of Benlysta, darapladib, albiglutide and HGS's pipeline and financial assets. -It also reflects expected cost synergies of at least $200 million. -Shares at 1723 GMT down 1%, at 1409 pence, valuing the company at GBP71 billion. -By Mark Shapland, Dow Jones Newswires; +44 207 8429358; mark.shapland@dowjones.com

Stock News for Human Genome Sciences (HGSI)
DateTimeHeadline
08/03/201203:00:56GlaxoSmithKline Completes Acquisition of Human Genome Sciences
07/30/201209:06:49GlaxoSmithKline Gets 79% Tenders for Human Genome Sciences Offer
07/15/201219:10:13Glaxo Eyes Human Genome Sciences for $2.6 Billion
07/15/201215:49:18Sources Say GlaxoSmithKline in Talks to Acquire Human Genome...
07/11/201212:36:14Glaxo To File Experimental Diabetes Drug Albiglutide In Early...
07/10/201208:38:08Human Genome: FDA Sets Dec. 15 Action Date For Anthrax Treatment...
07/03/201217:08:09GlaxoSmithKline Readies Candidates to Replace Human Genome's...
06/29/201209:24:03Glaxo Keeps Pressure On Human Genome By Extending Offer To July...
06/29/201207:35:49GlaxoSmithKline Sets July 20 For Expiration Of Tender Offer To...
06/15/201210:42:11GSK Gets Renewed Invitation to Human Genome Sciences Strategic...
06/08/201209:10:55GlaxoSmithKline Extends HGS Offer To June 29
06/07/201211:43:24Glaxo Seen Likely to Extend Hostile Tender Offer for Human Genome
05/30/201211:58:59GlaxoSmithKline Is Said To Plan Effort To Replace Human Genome...
05/23/201209:12:46Glaxo Amends Offer To Address HGS Shareholder Rights Plan
05/17/201217:45:35ADR Report: Shares Lower As Euro-Zone Worries Loom
05/17/201213:54:16GlaxoSmithKline Offer To Acquire HGS Represents Full, Fair Value
05/17/201207:55:44Human Genome Adopts Poison Pill With 15% Trigger To Deter Glaxo
05/09/201209:33:24WSJ BLOG/Health: A.M. Vitals: GSK's Hostile Human Genome Bid;...
05/09/201205:02:12Glaxo Goes Direct To HGS Shareholders With Hostile Offer
05/09/201202:48:24GlaxoSmithKline To Launch $13/Share Tender Offer For To Buy HGS

Human Genome Sciences and other NASDAQ stock quotes are delayed by at least 20 minutes.
All other stock price and quote data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad